<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01102439</url>
  </required_header>
  <id_info>
    <org_study_id>10-082</org_study_id>
    <nct_id>NCT01102439</nct_id>
  </id_info>
  <brief_title>Clopidogrel/Aspirin Interaction Study</brief_title>
  <acronym>INTERACTION</acronym>
  <official_title>Randomized, Factorial Study to Explore Interaction Between Aspirin and Clopidogrel in Stable Patients With Previous Myocardial Infarction or Coronary Artery Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore the effect of different doses of aspirin on the effects of
      double-dose or standard dose clopidogrel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Hypothesis: Patients receiving double-dose compared with standard-dose clopidogrel will
      have increased blood concentrations of the active metabolite of clopidogrel and greater
      inhibition of ADP-induced platelet aggregation when also treated with acetylsalicylic acid
      (ASA) 325 mg/d as compared to ASA 81 mg/d.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood concentrations of the active metabolite of clopidogrel</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inhibition of adenosine diphosphate (ADP) induced platelet aggregation</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Standard dose clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 mg Loading x 1 day, 75 mg/d x 13 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double dose clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg Loading x 1 day, 150 mg/d x 6 days, 75 mg/d x 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 81mg/d x 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin 325 mg/d x 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>300 mg loading dose, then 75 mg daily</description>
    <arm_group_label>Standard dose clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>600 mg loading dose, 150 mg daily day 2-7, then 75 mg daily</description>
    <arm_group_label>Double dose clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>81 mg daily</description>
    <arm_group_label>Standard dose aspirin</arm_group_label>
    <other_name>Entrophen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>325 mg daily</description>
    <arm_group_label>High dose aspirin</arm_group_label>
    <other_name>Novasen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 1 month post myocardial infarction (MI), unstable angina or stent patients with
             stable condition

          -  Receiving regular ASA (81mg/d) and clopidogrel (75mg/d) for at least 1 week

          -  Written informed consent

        Exclusion Criteria:

          -  Age &lt; 18 years old

          -  Liver disease with transaminases and/or bilirubin &gt; 1.5x upper limits of normal (ULN)
             (within 3 months of randomization)

          -  Renal impairment with creatinine clearance &lt; 30 ml/min (within 3 months of
             randomization)

          -  Platelet count &lt; 100x109/L and/or Hb&lt; 100g/L (within 3 months of randomization)

          -  Use of oral anticoagulants or nonsteroidal antiinflammatory drug (NSAID) within the
             last 10 days or planned use during the study

          -  Use of antiplatelet agent other than aspirin and clopidogrel within the last 10 days

          -  High risk of bleeding (e.g. recent gastrointestinal bleeding, bleeding diathesis)

          -  Uncontrolled hypertension (&gt; 180/110mmHg)

          -  Current smoker with â‰¥ 5 cigarettes/day

          -  Previously entered in this study or just finished other study within 2 weeks before
             recruitment

          -  Medical, geographic, or social factors making study participation impractical, or
             inability to provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Liang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Eikelboom, MD.</last_name>
    <role>Study Director</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Population Health Research Institute</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2010</study_first_submitted>
  <study_first_submitted_qc>April 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2010</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Population Health Research Institute</investigator_affiliation>
    <investigator_full_name>John Eikelboom</investigator_full_name>
    <investigator_title>MD.</investigator_title>
  </responsible_party>
  <keyword>Clopidogrel</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

